nach oben

Erschienen in:

15.03.2022 | Rektumkarzinom | Zertifizierte Fortbildung

Darmkrebs

Epidemiologie, Diagnostik und Therapie des Rektumkarzinoms

verfasst von: Maurice Vuattoux, Soleen Stocker-Ghafoor, Hatice Bunea, Christoph Kettelhack, Andreas Wicki, Prof. Dr. med. Frank B. Zimmermann

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

Die Therapie des Rektumkarzinoms befindet sich im Wandel. Für viele Betroffene läuft dies auf eine Intensivierung der präoperativen Therapie hinaus. Trotz erhöhter Nebenwirkungsraten ist die postoperative Morbidität gut zu handhaben. Durch die frühzeitige Therapie von subklinischen Metastasen und eine zunehmende Remission des Primärtumors konnte das krankheitsfreie Überleben und die intrapelvine Tumorkontrolle in den letzten Jahren deutlich verbessert werden. Über aktuelle Entwicklungen und den derzeitigen Standard in Diagnostik, Therapie und Nachsorge beim Rektumkarzinom lesen Sie in dieser Übersicht. …

Emrich K, Kraywinkel K. Epidemiologie des Rektumkarzinoms in Deutschland: Gibt es einen Anstieg des Rektumkarzinoms bei jungen Erwachsenen? Onkologe. 2020;26(12):1085-94

Robert Koch-Institut Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland 2015/2016. 2019; https://doi.org/10.25646/5977 abgerufen am 11. Februar 2022

Araghi M et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2019;144(12):2992-3000

Dekker E et al. Colorectal Cancer. Lancet. 2019; 394(10207):1467-80

Majek O et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer. 2012;106(11):1875-80

Garcia-Aguilar J et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. ASCO. 2020;Abstr 4008

www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom/ abgerufen am 10. Februar 2022

Guo F et al. Strong Reduction of Colorectal Cancer Incidence and Mortality After Screening Colonoscopy: Prospective Cohort Study From Germany. Am J Gastroenterol. 2021;116(5):967-75

Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland. Zi-Jahresbericht 2019: Früherkennungskoloskopien in Deutschland. https://www.zi.de/fileadmin/pdf/Koloskopie_Jahresbericht_2018.pdf abgerufen am 10. Februar 2022

10.

Ang CW et al. The diagnostic value of digital rectal examination in primary care for palpable rectal tumour. Colorectal Dis. 2008;10(8):789-92

11.

Bujko K et al. Rectal Cancer. Guidelines for diagnostic and therapeutic management. Oncol Clin Practice. 2020;16(6):338-57

12.

Maffione AM et al. Is it time to introduce PET/CT in rectal cancer guidelines? Clin Nuclear Med. 2020;45(8):611-7

13.

Chan BPH et al. EUS versus magnetic resonance imaging in staging rectal adenocarcinoma: a diagnostic test accuracy meta-analysis. Gastrointest Endosc. 2019;90(2):196-203.e1

14.

Luglio G et al. Endorectal Ultrasonography and Pelvic Magnetic Resonance Imaging Show Similar Diagnostic Accuracy in Local Staging of Rectal Cancer: An Update Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021;12(1):5

15.

Lee BC et al. Clinicopathological features and surgical options for synchronous colorectal cancer Medicine (Baltimore). 2017;96(9):e6224

16.

Haak HE et al. Modern MR Imaging Technology in Rectal Cancer; There Is More Than Meets the Eye. Front Oncol. 2020;10:537532

17.

Keller DS et al. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17(7):414-29

18.

Arya S et al. Imaging and Management of Rectal Cancer. Semin Ultrasound CT MR. 2020;41(2):183-206

19.

Zhuang L et al. Magnetic Resonance Imaging Evaluation of the Accuracy of Various Lymph Node Staging Criteria in Rectal Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:709070

20.

Detering R et al. MRI cT1-2 rectal cancer staging accuracy: a population-based study. Br J Surg. 2020;107(10):1372-82

21.

Giesen LJX et al. Effect of understaging on local reccurence of rectal cancer. J Surg Oncol. 2020;122(6):1179-86

22.

Park SH et al. MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice form the Korean Society of Abdominal Radiology. Korean J Radiol. 2020;21(7):812-28

23.

Renzulli M et al. Imaging of Colorectal Liver Metastases: New Developments and Pending Issues. Cancers. 2020;12(1):151

24.

Morin C et al. Additional value of gadoxetic acid-enhanced MRI to conventional extracellular gadolinium-enhanced MRI for the surgical management of colorectal and neuroendocrine liver metastases. HPB (Oxford). 2020;22(5):710-5

25.

Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479-82

26.

Branda ME et al. Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2019;269(4):589-95

27.

Conticchio M et al. Laparoscopic vs. open mesorectal excision for rectal cancer: Are these approaches still comparable? A systematic review and meta-analysis PLoS One. 2020;15(7):e0235887

28.

Varela C, Kim NK. Surgical Treatment of Low-Lying Rectal Cancer: Updates. Ann Coloproctol. 2021;37(6):395-424

29.

Hasegawa S et al. Transanal TME: new standard or fad? J Anus Rectum Colon. 2019;3(1):1-9

30.

Folkesson J et al. Swedish Rectal Cancer Trial: Long Lasting Benefits From Radiotherapy on Survival and Local Recurrence Rate. J Clin Oncol. 2005;23(24):5644-50

31.

van Gijn W et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82

32.

Erlandsson J et al. Tumor regression after radiotherapy for rectal cancer - results from the randomized Stockholm III trial. Radiother Oncol. 2019;135:178-86

33.

Sauer R et al. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. J Clin Oncol. 2012;30(16):1926-33

34.

Bosset JF et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184-90

35.

Bujko K et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215-23

36.

Ngan SY et al. Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol. 2012;30(31):3827-33

37.

Latkauskas T et al. Preoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer: results of a randomized controlled trial. BMC Cancer. 2016;16(1):927

38.

Marechal J et al. Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis. Medicine. 2019;98(17):e15241

39.

Conroy T et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cacner (UNICANCER-PRODIGE23). Lancet Oncol. 2021;22(5):702-15

40.

Rödel C et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979-89

41.

Deng et al. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. J Clin Oncol. 2019;37(34):3223-33

42.

Allegra CJ et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11):djv248

43.

Jiao D et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res. 2015;27(6):588-96

44.

Zheng et al. Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer. Medicine (Baltimore). 2017;96(13):e6487

45.

Petrelli F et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. Ann Surg. 2020;271(3):440-48

46.

Kairevice L et al. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer. Medicina (Kaunas). 2017;53(3):150-8

47.

Ciseł B et al. Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30(8):1298-303

48.

Jin J et al. A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-termn chemoradiotherapy in locally advanced rectal cancer (STELLAR): the final reports. ASCO. 2021;Abstr 3510

49.

Bahadoer RR et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO). Lancet Oncol. 2021;22(1):29-42

50.

Fernandez-Martos C et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015;26(8):1722-8

51.

Marechal R et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23(6):1525-30

52.

Garcia-Aguilar J et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicenter phase 2 trial. Lancet Oncol. 2015;16():957-66

53.

Fokas E et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212-22

54.

Fokas E et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022;8(1):e215445

55.

Liu S et al. Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist. 2021;26(9):e1555-e1566

56.

Giglio V et al. Published randomized controlled trials of surveillance in cancer patients - a systematic review. Oncol Review. 2021;15(1):522

57.

On J et al. Systematic review and meta-analysis on outcomes of salvage therapy in patients with tumour recurrence during 'watch and wait' in rectal cancer. Ann R Coll Surg Engl. 2019;101(7):441-52

58.

Pugh SA et al. Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial. Ann Surg. 2016;263(6):1143-7

59.

Benson AB et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806-15

60.

Glynne-Jones R et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv22-iv40

61.

Egenvall M et al. No benefit of more intense follow-up after surgery for colorectal cancer in the risk group with elevated CEA levels - an analysis within the COLOFOL randomized clinical trial. Eur J Surg Oncol. 2021;47(8):2053-9

62.

Lepage et al. Surveillance of colorectal cancers following curative-intent surgery: "Whatever the cost?" Dig Liver Dis. 2022;S1590-8658(21)00891-4

63.

Qaderi SM et al. Major differences in follow-up practice of patients with colorectal cancer; results of a national survey in the Netherlands. BMC Cancer. 2020;20(1):22

64.

Mir ZM et al. Management of rectal cancer in Canada: an evidence-based comparison of clinical practice guidelines. Can J Surg. 2020;63(1):E27-E34

65.

Wang X et al. Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer: Meta-analysis with trial sequential analysis of long-term survival data. PLoS One. 2018;13(7):e0200142

66.

Yuval J et al. Organ Preservation in Rectal Cancer. J Gastrointest Surg. 2020 ;24(8):1880-8

67.

Thompson H et al. Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial. ASCO. 2021;Abstr 3509

68.

Podda M et al. Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project. World J Emerg Surg. 2021;16(1):35

Titel: Darmkrebs
Epidemiologie, Diagnostik und Therapie des Rektumkarzinoms
verfasst von: Maurice Vuattoux
Soleen Stocker-Ghafoor
Hatice Bunea
Christoph Kettelhack
Andreas Wicki
Prof. Dr. med. Frank B. Zimmermann
Publikationsdatum: 15.03.2022
Verlag: Springer Medizin
Schlagwörter: Rektumkarzinom
Rektumkarzinom
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 3/2022
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-022-8969-7

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Erfolgreiche Kombinationstherapie bei Hirnmetastasen

BTK-Inhibitor bei Morbus Waldenström zugelassen

Adagrasib in der palliativen Erstlinientherapie des Pankreaskarzinoms

Optionen für fitte Patienten

Prophylaxe ohne Calcineurininhibitoren

CAR-T-Zellen als Zweitlinientherapie